A New Frontier in Cancer Pain Relief: Autonomix to Unveil Long-Term Data

THE WOODLANDS, TX – April 22, 2026 – For patients grappling with the agonizing pain of pancreatic cancer, a glimmer of hope is emerging from an innovative medical technology. Autonomix Medical, a Texas-based device company, announced today that it will present new, long-term clinical data on a minimally invasive procedure designed to provide durable pain relief. The findings will be unveiled at the prestigious European Conference on Interventional Oncology (ECIO) 2026 in Basel, Switzerland, later this month.

The presentation focuses on the company's first-in-class transvascular radiofrequency (RF) ablation system, a technology aimed at silencing the nerve signals that cause the severe, persistent pain associated with pancreatic adenocarcinoma. This announcement signals a potentially critical advancement in a field where effective, long-lasting solutions have remained elusive, leaving many patients reliant on high-dose opioids with significant side effects.

The Unyielding Challenge of Pancreatic Cancer Pain

Pancreatic cancer is notoriously difficult to treat, and one of its most devastating hallmarks is severe pain. More than 75% of patients experience significant pain at the time of diagnosis, a figure that climbs to over 90% in advanced stages. This pain, often described as a deep, boring ache radiating from the abdomen to the back, stems from the tumor invading or pressing against the celiac plexus, a complex network of nerves located behind the pancreas.

For decades, the standard of care has been a combination of powerful opioid medications and interventional procedures. While opioids are a cornerstone of pain management, they often come with a heavy burden of side effects, including constipation, nausea, fatigue, and cognitive impairment, which can further diminish a patient's quality of life. Furthermore, as the disease progresses, ever-increasing doses are often required to maintain control.

Interventional techniques like celiac plexus neurolysis (CPN), where a neurolytic agent like alcohol is injected to destroy the nerve tissue, can offer more targeted relief. However, the effectiveness of these procedures can be variable, and the pain relief is often temporary, typically lasting only a few months before the nerves regenerate or the cancer advances. This leaves a significant unmet medical need for a safer, more precise, and, most importantly, more durable solution.

"Current options are a trade-off. We can manage the pain, but often at the cost of the patient's alertness and comfort due to medication side effects," commented one pain management specialist not involved with the company. "A procedure that offers lasting relief without those trade-offs would be a monumental step forward."

A Novel Transvascular Approach to Pain Relief

Autonomix Medical is pioneering a radically different strategy. Instead of accessing the celiac plexus with a needle through the skin and other organs, its system uses a transvascular route. A sophisticated catheter is guided through the body’s vascular system—its natural highways—to reach the nerves responsible for transmitting pain signals from the pancreas.

What makes the technology unique is its catheter-based microchip sensing array. The company states this proprietary sensor can detect and differentiate neural signals with far greater sensitivity than existing technologies. This allows physicians to, for the first time, precisely map the target nerves before delivering highly focused radiofrequency (RF) energy to ablate, or deactivate, them. This precision targeting is designed to maximize pain relief while minimizing damage to surrounding healthy tissue.

Initial results from the company's first-in-human studies have been highly encouraging. Data presented earlier this year at the ASCO Gastrointestinal Cancers Symposium showed that the procedure provided statistically significant pain relief within 24 hours. In one cohort, 100% of responding patients achieved zero opioid use seven days after the procedure, with 73% remaining opioid-free at their four-to-six-week follow-up. The upcoming ECIO presentation, titled “Pain mitigation in pancreatic adenocarcinoma: a long-term analysis of denervation via transvascular RF energy-based ablation,” is expected to build on this foundation by providing crucial data on the durability of these outcomes over a longer period.

Beyond Pain: A Platform for Broader Medical Innovation

The implications of Autonomix's technology could extend far beyond pancreatic cancer. The company views its system as a broad platform with the potential to revolutionize the diagnosis and treatment of numerous diseases involving the peripheral nervous system. Success in this challenging initial indication would serve as powerful validation for the entire approach.

Investors have taken note of this potential. The company successfully launched its initial public offering (IPO) on the NASDAQ exchange in early 2024, raising capital to advance its clinical programs. Based on the strength of its initial data, Autonomix has already expanded its clinical trial protocol to include pain management for other visceral cancers that signal through the celiac plexus, effectively doubling its immediate addressable market.

Looking further ahead, the company has identified potential applications in cardiology, hypertension, and other chronic pain conditions. The ability to precisely sense and treat nerves transvascularly could open up new therapeutic avenues across a wide spectrum of medicine. Autonomix is charting a clear regulatory path, with plans to make a De novo submission to the U.S. Food and Drug Administration (FDA) in 2026, targeting potential market clearance in 2027.

This strategic vision places the upcoming data presentation in a much larger context. Positive long-term results would not only be a win for cancer patients but would also bolster confidence in the platform's viability for future, larger markets.

The Evolution of Interventional Oncology

Autonomix's work is emblematic of a broader shift in cancer care toward minimally invasive, highly targeted therapies. This field, known as interventional oncology, is increasingly recognized as the fourth pillar of cancer treatment, standing alongside medical, surgical, and radiation oncology.

Instead of systemic drugs or large open surgeries, interventional oncologists use image guidance to deliver treatments directly to tumors or, in this case, to the sources of debilitating symptoms. The goal is to maximize therapeutic effect while minimizing collateral damage and improving patient recovery and quality of life.

The presentation at ECIO, a premier global meeting for this specialty, is a fitting venue. The conference highlights groundbreaking research and technologies that are pushing the boundaries of what is possible in cancer care. The session featuring Autonomix's data, “Y90 and Novel Therapies,” places it among the most advanced and promising new treatments in the field.

All eyes in the oncology community will be on Basel for the presentation by Nikola Cesarovic, PhD. The long-term data could confirm that this novel transvascular ablation technique is not just a temporary fix, but a durable and meaningful advancement, heralding a new and more hopeful era for managing one of cancer's most feared symptoms.